Sildenafil Use in WHO Group 1 Pulmonary Arterial Hypertension

Indications and Strength of Recommendation

• Sildenafil is recommended as first‑line oral monotherapy for adult patients with WHO Group 1 PAH, initiated at 20 mg three times daily (TID) with escalation to a maximum of 80 mg TID if the clinical response is inadequate【1】【2】.
• In treatment‑naïve patients with WHO functional class (FC) II‑III who are not candidates for, or have failed, calcium‑channel blocker therapy, sildenafil improves 6‑minute walk distance (6MWD) and WHO FC【3】【2】.
• This recommendation carries a Grade 1C rating (strong recommendation, low‑quality evidence) for improving exercise capacity in WHO FC II‑III patients【3】【4】.

Hemodynamic Benefits

• Sildenafil reduces mean pulmonary arterial pressure and pulmonary vascular resistance, indicating favorable cardiopulmonary hemodynamic effects【1】【2】.

Comparative Effectiveness

• No oral PAH agent (endothelin receptor antagonist, PDE5 inhibitor, or riociguat) can be definitively preferred over another because of insufficient comparative data【1】.

Dosing and Titration

• Start dose: 20 mg orally TID, spaced 4–6 hours apart【1】【2】.
• Escalation: If the response is insufficient, increase by 20 mg increments up to 80 mg TID【1】【2】.
• Clinical trials demonstrate a dose‑response relationship for hemodynamic parameters up to 80 mg TID【1】.

Assessment and Monitoring

Baseline Evaluation

• Right‑heart catheterization to confirm PAH diagnosis and obtain baseline hemodynamics【1】.
• 6‑minute walk test to assess exercise capacity【1】【3】.
• WHO functional class assessment【1】【3】.

Follow‑up Monitoring

• Re‑evaluate at 2–3 months (or 3 months) using 6MWD, WHO FC, and symptom review【1】【5】.
• Monitor for clinical worsening (death, lung transplantation, PAH‑related hospitalization, or need for additional therapy)【3】.
• No routine laboratory monitoring is required for sildenafil, unlike endothelin receptor antagonists【1】.

Adverse Effects

• The most common mild‑to‑moderate adverse events are headache and dyspepsia【6】【7】.

Drug Interactions and Contraindications

• Concomitant use of riociguat is contraindicated because of the risk of severe systemic hypotension【1】【2】.

Alternative First‑Line Oral Options (for reference)

Parenteral Prostanoid Therapy for Severe Disease

• For WHO FC III patients with rapid progression or poor prognostic markers, consider continuous IV epoprostenol (Grade 2B) or IV/subcutaneous treprostinil (Grade 2B)【1】【3】.
• For WHO FC IV patients, initial parenteral prostanoid therapy is advised【4】.

Combination Therapy Strategies

• Adding sildenafil to stable IV epoprostenol increased 6MWD by 29 m (95 % CI 13.9–43.8 m), with greater benefit when baseline 6MWD > 325 m【6】【7】.
• Adding inhaled treprostinil to a stable ERA or PDE5 inhibitor improved 6MWD by 20 m in WHO FC III patients (Grade 2C)【3】【7】.
• Adding tadalafil to bosentan yielded a non‑significant 6MWD improvement of 23 m (95 % CI 2–48, p = 0.09), suggesting limited additive benefit【6】【7】.

Limitations of Use

• The efficacy of sildenafil has not been adequately evaluated in patients receiving bosentan; combination therapy with bosentan shows minimal additional benefit【6】【7】.

Practical Pitfalls

• Only 5–10 % of PAH patients are vasoreactive; avoid empiric sildenafil without vasoreactivity testing in potential calcium‑channel blocker candidates【3】.
• Do not combine sildenafil with nitrates (absolute contraindication due to life‑threatening hypotension).
• Do not combine sildenafil with riociguat (risk of severe systemic hypotension)【1】【2】.
• Counsel male patients to avoid using additional PDE5 inhibitors for erectile dysfunction while on sildenafil for PAH【1】.
• Expect less pronounced response in PAH associated with systemic‑sclerosis spectrum diseases compared with idiopathic PAH【1】.